Youth Depression Alleviation‐Augmentation with an anti‐inflammatory agent (<scp>YoDA‐A</scp>): protocol and rationale for a placebo‐controlled randomized trial of rosuvastatin and aspirin
Amelia L. Quinn(The University of Melbourne), Michael Berk(The Royal Melbourne Hospital), Simon Rice(The University of Melbourne), Francesco Giorlando(The University of Melbourne), Sue Cotton(Monash University), Shelley Baird(The University of Melbourne), Aswin Ratheesh(The University of Melbourne), Melissa Kerr(The University of Melbourne), Olivia Dean(Antwerp University Hospital), Seetal Dodd, Andrew M. Chanen(Orygen Youth Health), Christopher G. Davey(The University of Melbourne), Patrick D. McGorry(Orygen Youth Health), Mark Phelan(Orygen), G. Paul Amminger(The University of Melbourne), Susy Harrigan(Orygen Youth Health), Sarah Hetrick(University of Auckland), Melissa O’Shea(Deakin University), Miriam R. Schäfer(Medical University of Vienna), Andrew Mackinnon(Black Dog Institute)
Cited by 20
Related Papers
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
|The Lancet Psychiatry|2019|1.5k
So depression is an inflammatory disease, but where does the inflammation come from?
|BMC Medicine|2013|1.4k
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
|Bipolar Disorders|2012|1.2k
The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders
|American Journal of Psychiatry|2013|754